PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the clinical efficacy of inhaled triple therapy in the treatment of stable chronic obstructive pulmonary disease (COPD).
UNASSIGNED: This is a clinical comparative study. A total of 80 patients with COPD admitted to the First People\'s Hospital of Suining City from June 2020 to June 2023 were included and randomly divided into the study (conventional COPD treatment + inhaled triple therapy) and control (conventional COPD treatment) groups. The clinical efficacy of inhaled triple therapy and adverse reactions of the two groups to the treatment were observed. Clinical efficacy was assessed through changes in pulmonary function indexes, and comparisons of T lymphocyte subsets and serum inflammatory markers were conducted. In addition, St George\'s Respiratory Questionnaire (SGRQ) was employed for the quality-of-life assessment.
UNASSIGNED: The study group showed a significantly higher total efficacy than the control group (P < 0.05), with no significant difference in terms of adverse reactions between them (P > 0.05). After treatment, the study group showed better improvement in pulmonary function indexes, such as forced expiratory volume in one second (FEV1), FEV1 as a percentage of the expected value, forced vital capacity (FVC) and FEV1/FVC, compared with the control group (all P < 0.05). In addition, the study group presented higher levels of T lymphocyte subsets CD3+, CD4+ and CD4+/CD8+ than the control group(all P < 0.05). After treatment, the levels of inflammatory markers tumour necrosis factor-α, leukotriene B4 LTB4 and interleukin-6 in the study group decreased more than those in the control group (all P < 0.05). Moreover, the study group attained a lower SGRQ score than the control group (all P < 0.05).
UNASSIGNED: Triple inhalants further improve the clinical efficacy of the treatment of COPD.
UNASSIGNED: This is a clinical comparative study. A total of 80 patients with COPD admitted to the First People\'s Hospital of Suining City from June 2020 to June 2023 were included and randomly divided into the study (conventional COPD treatment + inhaled triple therapy) and control (conventional COPD treatment) groups. The clinical efficacy of inhaled triple therapy and adverse reactions of the two groups to the treatment were observed. Clinical efficacy was assessed through changes in pulmonary function indexes, and comparisons of T lymphocyte subsets and serum inflammatory markers were conducted. In addition, St George\'s Respiratory Questionnaire (SGRQ) was employed for the quality-of-life assessment.
UNASSIGNED: The study group showed a significantly higher total efficacy than the control group (P < 0.05), with no significant difference in terms of adverse reactions between them (P > 0.05). After treatment, the study group showed better improvement in pulmonary function indexes, such as forced expiratory volume in one second (FEV1), FEV1 as a percentage of the expected value, forced vital capacity (FVC) and FEV1/FVC, compared with the control group (all P < 0.05). In addition, the study group presented higher levels of T lymphocyte subsets CD3+, CD4+ and CD4+/CD8+ than the control group(all P < 0.05). After treatment, the levels of inflammatory markers tumour necrosis factor-α, leukotriene B4 LTB4 and interleukin-6 in the study group decreased more than those in the control group (all P < 0.05). Moreover, the study group attained a lower SGRQ score than the control group (all P < 0.05).
UNASSIGNED: Triple inhalants further improve the clinical efficacy of the treatment of COPD.
摘要：
■探讨吸入三联疗法治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。
■这是一项临床比较研究。纳入遂宁市第一人民医院2020年6月至2023年6月收治的80例COPD患者,随机分为研究组(COPD常规治疗+吸入三联疗法)和对照组(COPD常规治疗)。观察两组患者吸入三联疗法的临床疗效及不良反应。通过肺功能指标的变化来评估临床疗效，并比较T淋巴细胞亚群和血清炎症指标。此外,采用圣乔治呼吸问卷（SGRQ）进行生活质量评估。
■研究组总疗效明显高于对照组(P<0.05),两组不良反应比较差异无统计学意义(P>0.05)。治疗后,研究组肺功能指标改善较好,如一秒钟用力呼气量（FEV1），FEV1占期望值的百分比，强迫肺活量(FVC)和FEV1/FVC，与对照组比较(均P<0.05)。此外,研究组呈现较高水平的T淋巴细胞亚群CD3+，CD4+和CD4+/CD8+均优于对照组(均P<0.05)。治疗后,炎症标志物肿瘤坏死因子-α的水平，研究组白三烯B4LTB4、白细胞介素-6较对照组下降更多(均P<0.05)。此外，研究组SGRQ评分低于对照组(均P<0.05)。
■三联吸入剂进一步提高COPD治疗的临床疗效。
■这是一项临床比较研究。纳入遂宁市第一人民医院2020年6月至2023年6月收治的80例COPD患者,随机分为研究组(COPD常规治疗+吸入三联疗法)和对照组(COPD常规治疗)。观察两组患者吸入三联疗法的临床疗效及不良反应。通过肺功能指标的变化来评估临床疗效，并比较T淋巴细胞亚群和血清炎症指标。此外,采用圣乔治呼吸问卷（SGRQ）进行生活质量评估。
■研究组总疗效明显高于对照组(P<0.05),两组不良反应比较差异无统计学意义(P>0.05)。治疗后,研究组肺功能指标改善较好,如一秒钟用力呼气量（FEV1），FEV1占期望值的百分比，强迫肺活量(FVC)和FEV1/FVC，与对照组比较(均P<0.05)。此外,研究组呈现较高水平的T淋巴细胞亚群CD3+，CD4+和CD4+/CD8+均优于对照组(均P<0.05)。治疗后,炎症标志物肿瘤坏死因子-α的水平，研究组白三烯B4LTB4、白细胞介素-6较对照组下降更多(均P<0.05)。此外，研究组SGRQ评分低于对照组(均P<0.05)。
■三联吸入剂进一步提高COPD治疗的临床疗效。
